

RNS Number : 1602A  
EKF Diagnostics Holdings PLC  
17 February 2014

**EKF Diagnostics Holdings plc  
("EKF" or the "Company")**

**Notice of Results**

EKF Diagnostics Holdings plc (AIM: EKF), the point-of-care diagnostics business, will announce results for the financial year ended 31 December 2013, on Wednesday 26 February 2014.

The management team will be hosting an analyst briefing on the day. Analysts who wish to attend should contact Lianne Cawthorne on +44(0)20 7933 8788 or email [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com) to register.

**EKF Diagnostics Holdings plc**

David Evans, Executive Chairman  
Julian Baines, CEO  
Paul Foulger, Finance Director

**Tel: 029 2071 0570**

Mob: 07740 084 452  
Mob: 07788 420 859  
Mob: 07710 989 255

**Canaccord Genuity Limited**

Lucy Tilley / Henry Fitzgerald-O'Connor / Julian Feneley

**Tel: 020 7523 8350**

**Walbrook PR Limited**

Paul McManus

Paul Cornelius

**Tel: 020 7933 8780**

Mob: 07980 541 893 or  
[paul.mcmanus@walbrookpr.com](mailto:paul.mcmanus@walbrookpr.com)  
Mob: 07866 384 707 or [paul.cornelius@walbrookir.com](mailto:paul.cornelius@walbrookir.com)

**About EKF Diagnostics Holdings plc - [www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)**

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

This information is provided by RNS  
The company news service from the London Stock Exchange

END

NORFMGMZVDZGDZM admin Notice of Results 21483419 A Mon, 02/17/2014 - 07:00 Advance  
Notice of Results EKF